Tren is an extremely androgenic hormone, and as a result well known for promoting androgenic side effects. Hair loss and acne in men who are predisposed are both possible. Body hair growth is also possible. If you are not genetically predisposed no amount of Tren on earth with cause these issues. The androgenic side effects of Tren are truly based on genetic response. When it comes to hair loss, if you are predisposed to male pattern baldness, meaning at some point you’re going to lose your hair regardless of steroid use , Tren is one of the fastest ways to ensure you lose your hair a little sooner.
Virilization is a serious androgenic side effect of Tren. It is very difficult for a woman to use Tren without some level of virilization and makes it a steroid that’s almost never recommended for female use.
Important Note: The 5-alpha reductase enzyme does not metabolize the Trenbolone hormone. This means 5-alpha reductase inhibitors like Finasteride will not affect the androgenicity of the hormone.
There may be an increased risk of minor birth defects in children whose mothers are exposed to progestins during the first trimester of pregnancy. The possible risk to the male baby is hypospadias, a condition in which the opening of the penis is on the underside rather than the tip of the penis. This condition occurs naturally in approximately 5 to 8 per 1,000 male births. The risk may be increased with exposure to MPA tablets. Enlargement of the clitoris and fusion of the labia may occur in female babies. However, a clear association between hypospadias, clitoral enlargement and labial fusion with use of MPA tablets has not been established.
In the first year of the Health and Osteoporosis, Progestin and Estrogen (HOPE) Study, 2,001 women (average age ± years), of whom 88 percent were Caucasian, were treated with either Premarin mg alone (n = 348), Premarin mg alone (n = 338), Premarin mg alone (n = 326) or PREMPRO mg/ mg (n = 331), PREMPRO mg/ mg (n = 331) or PREMPRO mg/ mg (n = 327). Results of evaluable endometrial biopsies at 12 months showed a reduced risk of endometrial hyperplasia or cancer in the PREMPRO treatment groups compared with the corresponding Premarin alone treatment groups, except for the PREMPRO mg/ mg and Premarin mg alone groups, in each of which there was only 1 case, see Table 7 .